Biomedical Science Letters (대한의생명과학회지)

The Korean Society for Biomedical Laboratory Sciences (대한의생명과학회)
권호 표지
DOI QR코드

DOI QR Code

A Comparative Study of [F-18] Florbetaben (FBB) PET Imaging, Pathology, and Cognition between Normal and Alzheimer Transgenic Mice

  • Thapa, Ngeemasara (Department of Health care and Science, College of Health Sciences, Dong-A University) ;
  • Jeong, Young-Jin (Department of Nuclear Medicine, Dong-A University Medical Center, Dong-A University College of Medicine) ;
  • Kang, Hyeon (Institute of Convergence Bio-Health, Dong-A University) ;
  • Choi, Go-Eun (Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan) ;
  • Yoon, Hyun-Jin (Department of Nuclear Medicine, Dong-A University Medical Center, Dong-A University College of Medicine) ;
  • Kang, Do-Young (Department of Nuclear Medicine, Dong-A University Medical Center, Dong-A University College of Medicine)
  • Received : 2019.02.08
  • Accepted : 2019.03.05
  • Published : 2019.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Alzheimer's disease (AD) is highly prevalent in dementia, with no specifically effective treatment having yet been discovered. Amyloid plaques are one of the key hallmarks of AD. Transgenic mouse models exhibiting Alzheimer's disease-like pathology have been widely used to study the pathophysiology of Alzheimer's disease. In this study, we showed an age-dependent correlation between cognitive function, pathological findings, and [F-18] Florbetaben (FBB) PET images. Nineteen transgenic mice (12 with AD, 7 with controls) were used for this study. We observed an increase in ${\beta}$-Amyloid deposition ($A{\beta}$) in brain tissue and [F-18] FBB amyloid PET imaging in the AD group. The [F-18] FBB data showed a mildly negative trend with cognitive function. Pathological findings were negatively correlated with cognitive functions. These finding suggests that amyloid beta deposition can be well-monitored with [F-18] FBB PET and a decline in cognitive function is related to the increase in amyloid plaque burden.

Keywords

References

  1. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR. Frequent amyloid deposition without significant cognitive impairment among the elderly. Archives of Neurology. 2008. 65: 1509-1517. https://doi.org/10.1001/archneur.65.11.1509
  2. Ashe KH. Learning and memory in transgenic mice modeling alzheimer's disease. Learning & Memory. 2001. 8: 301-308. https://doi.org/10.1101/lm.43701
  3. Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, Younkin L, Good MA, Bliss T, Hyman BT. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nature Neuroscience. 1999. 2: 271. https://doi.org/10.1038/6374
  4. Chatziioannou AF. Pet scanners dedicated to molecular imaging of small animal models. Molecular Imaging & Biology. 2002. 4: 47-63. https://doi.org/10.1016/S1095-0397(01)00067-X
  5. Choi GE, Yoon S-Y, Kim J-Y, Kang D-Y, Jang YJ, Kim HS. Autophagy deficiency in myeloid cells exacerbates eosinophilic inflammation in chronic rhinosinusitis. Journal of Allergy and Clinical Immunology. 2018. 141: 938-950. e912. https://doi.org/10.1016/j.jaci.2017.10.038
  6. Christie R, Yamada M, Moskowitz M, Hyman B. Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy. The American Journal of Pathology. 2001. 158: 1065-1071. https://doi.org/10.1016/S0002-9440(10)64053-9
  7. Drzezga A. Amyloid-plaque imaging in early and differential diagnosis of dementia. Annals of Nuclear Medicine. 2010. 24: 55-66. https://doi.org/10.1007/s12149-009-0330-9
  8. Elder GA, Gama Sosa MA, De Gasperi R. Transgenic mouse models of alzheimer's disease. The Mount Sinai Journal of Medicine. 2010. 77: 69-81. https://doi.org/10.1002/msj.20159
  9. Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D, Phelps ME, Weber WA. Impact of animal handling on the results of 18f-fdg pet studies in mice. Journal of Nuclear Medicine. 2006. 47: 999.
  10. Gordon MN, King DL, Diamond DM, Jantzen PT, Boyett KV, Hope CE, Hatcher JM, DiCarlo G, Gottschall WPE, Morgan D. Correlation between cognitive deficits and $A{\beta}$ deposits in transgenic app+ ps1 mice. Neurobiology of Aging. 2001. 22: 377-385. https://doi.org/10.1016/S0197-4580(00)00249-9
  11. Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: The challenge of the second century. Science Translational Medicine. 2011. 3: 77sr71-77sr71.
  12. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, $A{\beta}$ elevation, and amyloid plaques in transgenic mice. Science. 1996. 274: 99-103. https://doi.org/10.1126/science.274.5284.99
  13. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, csf, and plasma amyloid ${\beta}$ protein in the tg2576 transgenic mouse model of alzheimer's disease. Journal of Neuroscience. 2001. 21: 372-381. https://doi.org/10.1523/JNEUROSCI.21-02-00372.2001
  14. Khachaturian ZS. Diagnosis of alzheimer's disease. Archives of Neurology. 1985. 42: 1097-1105. https://doi.org/10.1001/archneur.1985.04060100083029
  15. King DL, Arendash GW, Crawford F, Sterk T, Menendez J, Mullan MJ. Progressive and gender-dependent cognitive impairment in the appsw transgenic mouse model for alzheimer's disease. Behavioural. Brain Research. 1999. 103: 145-162.
  16. Klunk WE, Engler H, Nordberg A, Bacskai BJ, Wang Y, Price JC, Bergstrom M, Hyman BT, Langstrom B, Mathis CA. Imaging the pathology of alzheimer's disease: Amyloid-imaging with positron emission tomography. Neuroimaging Clinics. 2003. 13: 781-789. https://doi.org/10.1016/S1052-5149(03)00092-3
  17. Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang G-F, Shao L. Binding of the positron emission tomography tracer pittsburgh compound-b reflects the amount of amyloid-${\beta}$ in alzheimer's disease brain but not in transgenic mouse brain. Journal of Neuroscience. 2005. 25: 10598-10606. https://doi.org/10.1523/JNEUROSCI.2990-05.2005
  18. Kuntner C, Kesner AL, Bauer M, Kremslehner R, Wanek T, Mandler M, Karch R, Stanek J, Wolf T, Muller M, Langer O. Limitations of small animal pet imaging with [18f]fddnp and fdg for quantitative studies in a transgenic mouse model of alzheimer's disease. Molecular Imaging and Biology. 2009. 11: 236-240. https://doi.org/10.1007/s11307-009-0198-z
  19. Manook A, Yousefi BH, Willuweit A, Platzer S, Reder S, Voss A, Huisman M, Settles M, Neff F, Velden J. Small-animal pet imaging of amyloid-beta plaques with [11c] pib and its multimodal validation in an app/ps1 mouse model of alzheimer's disease. PloS One. 2012. 7: e31310. https://doi.org/10.1371/journal.pone.0031310
  20. Miedel CJ, Patton JM, Miedel AN, Miedel ES, Levenson JM. Assessment of spontaneous alternation, novel object recognition and limb clasping in transgenic mouse models of amyloid-${\beta}$ and tau neuropathology. Journal of Visualized Experiments: JoVE. 2017.
  21. Molinuevo JL, Ayton S, Batrla R, Bednar MM, Bittner T, Cummings J, Fagan AM, Hampel H, Mielke MM, Mikulskis A. Current state of alzheimer's fluid biomarkers. Acta Neuropathologica. 2018. 1-33.
  22. Moran PM, Higgins LS, Cordell B, Moser PC. Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human beta-amyloid precursor protein. Proceedings of the National Academy of Sciences. 1995. 92: 5341-5345. https://doi.org/10.1073/pnas.92.12.5341
  23. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D. $A{\beta}$ peptide vaccination prevents memory loss in an animal model of alzheimer's disease. Nature. 2000. 408: 982. https://doi.org/10.1038/35050116
  24. Pompl PN, Mullan MJ, Bjugstad K, Arendash GW. Adaptation of the circular platform spatial memory task for mice: Use in detecting cognitive impairment in the appsw transgenic mouse model for alzheimer's disease. Journal of Neuroscience Methods. 1999. 87: 87-95. https://doi.org/10.1016/S0165-0270(98)00169-1
  25. Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R, Jones G, Maruff P, Woodward M, Price R. Predicting alzheimer disease with ${\beta}$-amyloid imaging: Results from the australian imaging, biomarkers, and lifestyle study of ageing. Annals of Neurology. 2013. 74: 905-913. https://doi.org/10.1002/ana.24040
  26. Snellman A, Lopez-Picon FR, Rokka J, Salmona M, Forloni G, Scheinin M, Solin O, Rinne JO, Haaparanta-Solin M. Longitudinal amyloid imaging in mouse brain with 11c-pib: Comparison of app23, tg2576, and appswe-ps1de9 mouse models of alzheimer disease. J Nucl Med. 2013. 54: 1434-1441. https://doi.org/10.2967/jnumed.112.110163
  27. Son HJ, Jeong YJ, Yoon HJ, Lee SY, Choi G-E, Park J-A, Kim MH, Lee KC, Lee YJ, Kim MK. Assessment of brain betaamyloid deposition in transgenic mouse models of alzheimer's disease with pet imaging agents 18 f-flutemetamol and 18 f-florbetaben. BMC Neuroscience. 2018. 19: 45. https://doi.org/10.1186/s12868-018-0447-7
  28. Takeuchi A, Irizarry MC, Duff K, Saido TC, Ashe KH, Hasegawa M, Mann DM, Hyman BT, Iwatsubo T. Age-related amyloid ${\beta}$ deposition in transgenic mice overexpressing both alzheimer mutant presenilin 1 and amyloid ${\beta}$ precursor protein swedish mutant is not associated with global neuronal loss. The American Journal of Pathology. 2000. 157: 331-339. https://doi.org/10.1016/S0002-9440(10)64544-0
  29. Tijms BM, Vermunt L, Zwan MD, van Harten AC, van der Flier WM, Teunissen CE, Scheltens P, Visser PJ, ADNI. Pre-amyloid stage of alzheimer's disease in cognitively normal individuals. Annals of Clinical and Translational Neurology. 2018. 5: 1037-1047. https://doi.org/10.1002/acn3.615
  30. Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S, Ackermann U, Cowie T, Currie J, Chan S. $A{\beta}$ deposits in older non-demented individuals with cognitive decline are indicative of preclinical alzheimer's disease. Neuropsychologia. 2008. 46: 1688-1697. https://doi.org/10.1016/j.neuropsychologia.2008.02.008